Publications
2018
2017
Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity.
2015
Late-onset sepsis in preterm infants: update on strategies for therapy and prevention.
2014
Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.
DOI: 10.1093/cid/ciu727
2012
Appropriate antibiotic therapy improves Ureaplasma sepsis outcome in the neonatal mouse.
DOI: 10.1038/pr.2012.115
2011
Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units.
A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis.
Assessment of intrapartum antibiotic prophylaxis for the prevention of early-onset group B Streptococcal disease.
2009
Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future.
Guidelines on CMV congenital infection.
DOI: 10.1515/JPM.2009.127
Antibiotic prophylaxis improves Ureaplasma-associated lung disease in suckling mice.
Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates.
DOI: 10.1128/AAC.01565-08
Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults.
Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults.
Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
2008
Population structure of invasive and colonizing strains of Streptococcus agalactiae from neonates of six U.S. Academic Centers from 1995 to 1999.
DOI: 10.1128/JCM.02105-07
Treatment and prevention of malaria in pregnancy and newborn.
DOI: 10.1515/JPM.2008.002
2007
Prophylaxis with lactoferrin, a novel antimicrobial agent, in a neonatal rat model of coinfection.
DOI: 10.1007/BF02877698
Antibody for the prevention of neonatal nosocomial staphylococcal infection: a review of the literature.
Patient isolation measures for infants with candida colonization or infection for preventing or reducing transmission of candida in neonatal units.
Lysostaphin in treatment of neonatal Staphylococcus aureus infection.
DOI: 10.1128/AAC.00506-06
Neonatal coinfection model of coagulase-negative Staphylococcus epidermidis and Candida albicans: fluconazole prophylaxis enhances survival and growth.
DOI: 10.1128/AAC.01298-06
Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient.
2006
Phylogenetic lineages of invasive and colonizing strains of serotype III group B Streptococci from neonates: a multicenter prospective study.
Prevention and treatment of respiratory syncytial virus infection in infants: an update.
2004
Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen.
DOI: 10.1086/422756
Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient.
Dexamethasone effects on group B streptococcal infection in newborn rats.
2003
Prematurity is the major risk factor for late-onset group B streptococcus disease.
DOI: 10.1086/376457
Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus.
2002
Current respiratory syncytial virus prevention strategies in high-risk infants.
2001
Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.
DOI: 10.1086/323350
The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease.
2000
Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995–1998.
DOI: 10.1086/313936
1999
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high-risk infants: a consensus opinion.
1998
Treatment of obstructive jaundice in erythroblastosis fetalis with ursodeoxycholic acid (UDCA): a case report.
Actuarial survival in the premature infant less than 30 weeks' gestation.
Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection.
DOI: 10.1086/517810
Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia.
1997
Resource utilization among neonatologists in a university children's hospital.
DOI: 10.1542/PEDS.99.6.E2